Compound News and Research

RSS

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Xencor, Inc. presented results Sunday at the 50th Annual Meeting of the American Society of Hematology from pre-clinical studies evaluating XmAb 5574, a monoclonal antibody engineered using Xencor's XmAb Fc technologies that targets the antigen CD19.

10 Dec 2008

Experimental drug successfully blocks mutation in bone marrow cancers

Oregon Health & Science University Knight Cancer Institute researchers have found that an experimental drug successfully blocks an enzyme that causes some bone marrow cancers.

10 Dec 2008

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AstraZeneca and Targacept, Inc. havey announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

10 Dec 2008

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Pregnancy and surgery patients with a serious blood disorder that causes excessive clotting have responded well to treatment with a man-made anti-clotting protein.

8 Dec 2008

Osmium as a cancer treatment

A precious metal which has never before been used in a clinical setting is being developed as an anti-cancer agent by University of Warwick researchers.

8 Dec 2008

Glowing imaging compound allows detection of viable cancer cells in mice

Researchers have developed a new type of imaging compound that allows them to visualize viable breast cancer cells that have spread to the lungs in mice.

8 Dec 2008

Hemichannels - new target to treat epileptic seizures following brain trauma or stroke

New therapies for some forms of epilepsy may soon be possible, thanks to a discovery made by a team of University of British Columbia and Vancouver Coastal Health Research Institute neuroscience researchers.

8 Dec 2008

ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%

ISTA Pharmaceuticals, Inc. has announced results from the Company's recently completed Phase III clinical program of Xibrom (0.09% bromfenac sodium ophthalmic solution) QD (once-daily).

8 Dec 2008

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

Incyte Corporation will present updated results from an ongoing Phase II trial of INCB18424, its selective, orally available Janus kinase (JAK) inhibitor, in patients with myelofibrosis (MF) at the 50th American Society of Hematology (ASH) Annual Meeting.

8 Dec 2008

New data demonstrates efficacy and tolerability of Carisbamate as an adjunctive therapy for partial onset seizures

Phase III data on carisbamate, an investigational compound recently filed with the FDA for the adjunctive treatment of partial onset seizures (POS) in patients 16 years of age and older, was presented during the poster sessions of the 32nd Annual Meeting of the American Epilepsy Society.

7 Dec 2008

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

7 Dec 2008

New set of controls for stem cells discovered

Natural changes in voltage that occur across the membrane of adult human stem cells are a powerful controlling factor in the process by which these stem cells differentiate, according to research published by Tufts University scientists.

3 Dec 2008

Broccoli compound, indole-3-carbinol targets key enzyme in late-stage cancer

An anti-cancer compound found in broccoli and cabbage works by lowering the activity of an enzyme associated with rapidly advancing breast cancer, according to a University of California, Berkeley, study appearing this week in the online early edition of the journal Proceedings of the National Academy of Sciences.

3 Dec 2008

More alkaline diet strengthens skeletal health

Diets that are high in protein and cereal grains produce an excess of acid in the body which may increase calcium excretion and weaken bones, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

3 Dec 2008

NicOx signs agreement with DSM for the commercial manufacture of naproxcinod drug substance

NicOx S.A. has announced it has signed an agreement with DSM for the commercial manufacture and supply of naproxcinod drug substance (or API, active pharmaceutical ingredient).

3 Dec 2008

Scientists discover new properties of imidazolium salts

Scientists at Singapore's Institute of Bioengineering and Nanotechnology (IBN) have uncovered new properties of imidazolium salts (IMSs), which suggest that they could play a vital role in disease prevention and treatment.

1 Dec 2008

Breakthrough in strategy used to develop new pharmacological treatments for schizophrenia

In one of the first instances of targeted drug design in psychiatric treatment, University of Pittsburgh researchers have found an experimental agent that shows promise in addressing working memory impairments that occur in schizophrenia.

1 Dec 2008

Etanercept found to be ineffective in treating alcoholic hepatitis

A new study from Mayo Clinic finds the use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, an acute inflammation of the liver caused by excessive consumption of alcohol. The results of the study are published in the December issue of Gastroenterology.

1 Dec 2008

Selenium may slow march of AIDS

Increasing the production of naturally occurring proteins that contain selenium in human blood cells slows down multiplication of the AIDS virus, according to biochemists.

30 Nov 2008

Researchers identify molecule that tells your brain your stomach is full

In studies with mice and rats, researchers have found that a chemical messenger called NAPE is made in the small intestine after the animals ate a greasy meal. After eating, NAPE - N-acylphosphatidylethanolamine, a mouthful in itself -- enters the blood and travels to the brain, where it quashes hunger signals.

26 Nov 2008

Compound News and Research

Xencor presents data on anti-CD19 and anti-CD40 antibodies

Experimental drug successfully blocks mutation in bone marrow cancers

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

Recombinant human antithrombin drug decreases risk to pregnancy and surgery patients with hereditary antithrombin deficiency

Osmium as a cancer treatment

Glowing imaging compound allows detection of viable cancer cells in mice

Hemichannels - new target to treat epileptic seizures following brain trauma or stroke

ISTA Pharmaceuticals announces trial results for topical Xibrom 0.09%

Incyte's selective Janus kinase inhibitor demonstrates rapid and durable clinical benefits in Myelofibrosis patients

New data demonstrates efficacy and tolerability of Carisbamate as an adjunctive therapy for partial onset seizures

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

New set of controls for stem cells discovered

Broccoli compound, indole-3-carbinol targets key enzyme in late-stage cancer

More alkaline diet strengthens skeletal health

NicOx signs agreement with DSM for the commercial manufacture of naproxcinod drug substance

Scientists discover new properties of imidazolium salts

Breakthrough in strategy used to develop new pharmacological treatments for schizophrenia

Etanercept found to be ineffective in treating alcoholic hepatitis

Selenium may slow march of AIDS

Researchers identify molecule that tells your brain your stomach is full

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News